Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

CJC-1295 No DAC Dosage Protocol | PeptideDosages.com

CJC-1295 NO DAC (5 mg Vial) Dosage Protocol CJC-1295 NO DAC Dosage Chart CJC-1295 NO DAC is dosed at 100 mcg–300 mcg daily via subcutaneous injection in educational protocols. A 5 mg vial reconstituted with bacteriostatic water yields about 1.67 mg/mL. This in

By Recovery & Performance Peptides Editorial Team

CJC-1295 NO DAC (5 mg Vial) Dosage Protocol

CJC-1295 NO DAC Dosage Chart

CJC-1295 NO DAC is dosed at 100 mcg–300 mcg daily via subcutaneous injection in educational protocols. A 5 mg vial reconstituted with bacteriostatic water yields about 1.67 mg/mL. This information is for research and educational use only.

Reconstitute: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration.

Typical daily range: 100–300 mcg once daily (gradual titration).

Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U‑100 insulin syringe.

Storage: Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F); after reconstitution, refrigerate and use within 1–2 weeks; for longer storage, freeze at ≤−20 °C (≤−4 °F).

CJC-1295 NO DAC dosage protocols leverage this synthetic 29‑amino‑acid GHRH analog (also known as Modified GRF 1–29 or Mod GRF) to stimulate natural, pulsatile growth hormone secretion from the pituitary gland[1][2]. Unlike exogenous GH administration, CJC-1295 NO DAC preserves the body’s physiologic feedback loop, supporting enhanced GH and IGF‑1 levels while maintaining natural hormonal rhythms[3][4]. Research suggests benefits may include improved body composition, enhanced recovery, better sleep quality, and support for lean muscle mass and metabolic function[5][6]. This educational protocol presents a practical once‑daily subcutaneous approach using a dilution optimized for clear insulin‑syringe measurements.

Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read CJC-1295 No DAC Peptide: Benefits, Uses, Side Effects, Dosage, and Research.

Standard / Gradual Approach (3 mL = ~1.67 mg/mL)

Weeks 1–2

100 mcg

6 units (0.06 mL)

Weeks 3–4

150 mcg

9 units (0.09 mL)

Weeks 5–6

200 mcg

12 units (0.12 mL)

Weeks 7–12

250–300 mcg

15–18 units (0.15–0.18 mL)

Frequency: Inject once daily subcutaneously, typically at bedtime to align with natural nocturnal GH pulsatility[2][3]. For ≤10‑unit (≤0.10 mL) administrations (Weeks 1–4), consider 30‑ or 50‑unit insulin syringes for improved readability.

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.

Inject slowly down the vial wall; avoid foaming.

Gently swirl/roll until dissolved (do not shake).

Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Supplies Needed

Plan based on an 8–12 week daily protocol with gradual titration.

Peptide Vials (CJC-1295 NO DAC, 5 mg each):

8 weeks ≈ 2 vials

12 weeks ≈ 3 vials

16 weeks ≈ 4 vials

Insulin Syringes (U‑100):

Per week: 7 syringes (1/day)

8 weeks: 56 syringes

12 weeks: 84 syringes

16 weeks: 112 syringes

Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.

8 weeks (2 vials): 6 mL → 1 × 10 mL bottle

12 weeks (3 vials): 9 mL → 1 × 10 mL bottle

16 weeks (4 vials): 12 mL → 2 × 10 mL bottles

Alcohol Swabs: One for the vial stopper + one for the injection site each day.

Per week: 14 swabs (2/day)

8 weeks: 112 swabs → recommend 2 × 100‑count boxes

12 weeks: 168 swabs → recommend 2 × 100‑count boxes

16 weeks: 224 swabs → recommend 3 × 100‑count boxes

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

PROCEDURE

How to Select the Perfect CJC-1295 no DAC Vial Size

So, how do you make the final call? It's about asking the right questions. Before you add anything to your cart, our team recommends you run through this mental checklist. First, what's the total duration of your experiment? If you're running a two-week study, buying a vial that will last for two months is counterproductive. The potency of the peptide on day 45 will not be the same as it was on day 1. Match the CJC-1295 no DAC vial size to your timeline. This is the single most important factor. Second, what is your daily or per-injection dosage? Do the math upfront. Calculate the total amount of peptide you'll need for the entire study. For example, a protocol requiring 100mcg twice a day for 14 days needs 2800mcg, or 2.8mg. In this scenario, purchasing a 5mg vial makes sense, while a 2mg vial would be insufficient. A clear understanding of your required quantity will guide your choice of CJC-1295 no DAC vial size. Third, how many subjects are in your study group? If you're dosing a dozen test subjects simultaneously, your consumption rate will be much higher, and a larger CJC-1295 no DAC vial size might be more practical. However, if it's a small-scale study, stick with smaller vials to maintain maximum integrity for each and every subject. Don't compromise your entire data set to save a few dollars. And another consideration: your lab's environment. Is your cold storage impeccably reliable? Is there a high volume of traffic in and out of the research fridge, increasing te…
DOSAGE SOURCE

CJC-1295 (no DAC) Dosage, Reconstitution & Mixing Trends

Explore CJC-1295 (no DAC) dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator data. 323 CJC-1295 (no DAC) reconstitution calculations have been logged by the WPA community. The most common dose entered is 200mcg (70 calculations). The most common bacteriostatic water volume is 2mL. The most popular vial size is 10mg (173 sessions). The most common dosing frequency is daily (7x/week) (25 logged protocols), followed by 5x/week (13). World Peptide Association aggregates anonymized peptide calculator data to show real-world dosing trends, reconstitution volumes, and vial size preferences across the research peptide community. All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.
02

Question drills

Open a question for its connected answer.

01What If I Feel Nauseous or Lightheaded After Fasted-State Administration?+

This is usually a transient effect of rapid GH release in a fasted state, particularly if you're administering on an empty stomach first thing in the morning. GH mobilises free fatty acids from adipose tissue, and the sudden rise in plasma FFAs can cause mild nausea in some individuals. If this occurs consistently, try administering the peptide 30 minutes after waking instead of immediately upon waking. This allows cortisol and blood glucose to stabilise slightly. If symptoms persist, consider splitting to a lower dose twice daily instead of a single higher dose.

SOURCE / realpeptides.co ↗
02What If I Want to Use It Long-Term?+

CJC-1295 no DAC is designed for sustained use because it preserves receptor sensitivity and endogenous GH pulsatility. Research protocols commonly run 6–12 months without evidence of tachyphylaxis (tolerance). The peptide does not suppress natural GHRH release or downregulate pituitary receptors when dosed correctly. For continuous long-term use, monitor serum IGF-1 every 8–12 weeks to confirm sustained elevation. IGF-1 should remain 20–40% above baseline if the protocol is effective. If IGF-1 plateaus or declines despite consistent dosing, the issue is typically preparation error (degraded peptide from improper storage) or timing error (doses not aligned with natural pulses), not receptor desensitisation.

SOURCE / realpeptides.co ↗
03What If My Fasting Glucose Rises from 95 mg/dL to 110 mg/dL at Week 8?+

Pause CJC-1295 administration for two weeks and retest fasting glucose and HbA1c. GH is insulin-antagonistic. It reduces peripheral glucose uptake while increasing hepatic glucose output. A 15 mg/dL rise in fasting glucose signals your insulin sensitivity can't compensate for the GH effect. If glucose normalizes during the pause, resume at 50% of the prior dose (e.g., 100mcg 2x weekly instead of 150mcg 3x weekly) and add structured carbohydrate timing around injections to prevent postprandial spikes.

SOURCE / realpeptides.co ↗
04What If My Research Results Don't Match Published CJC-1295 No DAC Studies?+

Verify peptide identity and purity first. Request the ESI-MS data from your supplier to confirm the molecular weight matches 3647.28 Da for CJC-1295 no DAC acetate salt. If the mass is incorrect, you're not working with the intended peptide. Second, confirm dosing frequency aligns with the 30-minute half-life. Single daily dosing will not replicate studies using multiple doses per day. Third, check storage conditions post-reconstitution: any temperature excursion invalidates the batch. If all three check out and results still diverge, examine your research model for strain differences, age, baseline GH status, or co-administered compounds that may modulate GHRH receptor sensitivity. Peptide quality is the first variable to control, but biological variability is the second.

SOURCE / realpeptides.co ↗
05What If I Feel Lightheaded or Nauseous After Fasted Injection?+

Lightheadedness is rare but can occur in individuals with baseline low blood pressure or orthostatic hypotension. The GH spike slightly raises blood sugar but doesn't directly affect vascular tone. If it occurs, sit or lie down for 5–10 minutes and consume 10–15 grams of fast-acting carbohydrate (glucose tablet, honey). Nausea affects 5–8% of users and typically resolves within 20–30 minutes as GH peaks and begins to decline. Neither symptom indicates a dangerous reaction. They reflect heightened autonomic sensitivity to rapid hormone shifts.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Are There Specific Protocols or Stacks for Research?

Absolutely, specific protocols and stacking strategies are common in CJC-1295 no DAC research. As mentioned, combining it with a GHRP like Ipamorelin is a very popular and effective approach. Researchers often administer both peptides simultaneously, usually 2-3 times daily, to maximize the pulsatile release of GH. This approach helps maintain elevated GH levels without causing pituitary desensitization, which is the whole point of using the 'no DAC' variant. For those exploring optimized stacks, our Tesamorelin + Ipamorelin Blend offers another compelling avenue for investigation. The timing of administration is often debated in the CJC-1295 no DAC FAQ, but many protocols suggest morning, post-workout, and before bed administrations to align with natural GH release patterns. We've seen various intricate protocols developed by researchers over the years, each aiming to fine-tune the GH response for specific study objectives. It’s not a 'one-size-fits-all' situation, and careful titration and observation are always recommended. Understanding these nuanced protocols is key to getting the most out of your CJC-1295 no DAC research.

RESEARCH

Practical Considerations for Research in 2026

Executing a research protocol with this peptide requires precision. It's not a set-it-and-forget-it compound. Because of its short half-life, administration timing is critical to align with the body's natural rhythms. Common research protocols often involve 2-3 administrations per day. The timing is strategic: Morning: Often done on an empty stomach to avoid blunting the GH pulse with insulin. Post-Workout: This timing leverages the body's heightened sensitivity to growth factors after training. Before Bed: This is arguably the most important administration, as it amplifies the largest natural GH pulse that occurs during the first few hours of deep sleep. Of course, any legitimate research begins with proper handling. Peptides like our CJC 1295 (no Dac) are delivered in a lyophilized (freeze-dried) state for stability. They must be reconstituted before use. This process involves carefully mixing the peptide powder with a sterile solvent. We can't stress this enough: the quality of your solvent matters. Using high-purity Bacteriostatic Reconstitution Water (bac) is non-negotiable for maintaining the integrity and sterility of the peptide. It’s a small detail that makes a world of difference in the reliability of your results. And that brings us to the most critical point of all: sourcing. In 2026, the market is flooded with peptides of questionable origin and purity. When your research into CJC-1295 no DAC for muscle growth depends on accuracy, you simply cannot afford impurities or incorrect peptide sequences. This is the entire reason Real Peptides exists. We built our reputation on an unwavering commitment to quality, with every batch synthesized in the U.S. and subjected to rigorous third-party testing to verify its purity and structure. You can see this dedication across all our offerings, from foundational compounds to more specialized blends found in our Muscle Building Research collection. This isn't just a product for us; it's a commitment to advancing legitimate scientific inquiry. Exploring CJC-1295 no DAC for muscle growth requires a partner you can trust implicitly.

05

Product & matchup locker

Linked catalog and comparison files.

Continue reading

Related articles